Fig. 5From: The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabChange of glycemia level over 3 months of treatment. PFS (A) and OS (B) in patients treated in the first line. PFS (C) and OS (D) in patients treated in the second or further lineBack to article page